Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom, Illumina Ink Supply Agreement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom today said that it has entered into a three-year supply agreement with Illumina for sequencing equipment and consumables.

Sequenom and its subsidiaries will purchase the Illumina products for use in developing its non-invasive trisomy 21 test. In addition, the firms intend to work collaboratively toward the submission of regulatory clearance of an in vitro diagnostic test for detecting fetal chromosomal abnormalities.

Sequenom has said that it plans to launch its SensiGene T21 test as a laboratory-developed test at the end of this year or in the first quarter of 2012. The firm also had previously disclosed that it had completed a validation study of its test on the Illumina HiSeq platform in 2,000 high-risk pregnancies, which will serve as the basis for the LDT.

"This agreement is an important step in bringing our proprietary trisomy test to market, giving us the scalability, speed to market, and supply chain necessary to address the commercial opportunity of our noninvasive prenatal test for trisomy 21," Sequenom Chairman and CEO Harry Hixson said in a statement.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.